Annals of Oncology 7:843-848, 1996
© 1996 European Society for Medical Oncology
research-article |
Serum basic fibroblast growth factor and vascular endothelial growth factor and tumour growth kinetics in advanced colorectal cancer
1Departments of Medical Oncology Wilrijk, Belgium
2Departments of Surgery, University Hospital Wilrijk, Belgium
3Department of Medical Oncology, Medisch Instituut Sint-Augustinus Antwerp Wilrijk, Belgium
4Departments of the Angiogenesis Group, Antwerp University (ULA) Wilrijk, Belgium
Correspondence to: Dr. Luc Y. Dirix Department of Medical Oncology University Hospital Antwerp Wilrijkstraat 10 B-2650 Edegem Belgium
BACKGROUND:: The development of new microvessels in the surrounding stroma is a prerequisite for tumour progression. Basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF) are angiogenic factors expressed in a broad range of human tumours. We have measured the concentrations of both cytokines in the serum of patients with advanced colorectal cancer. We questioned whether these levels are related to the number of tumour sites, the volume of liver and/or lung involvement and the growth kinetics.
PATIENTS AND METHODS:: 44 untreated colorectal adenocarcinoma patients who had developed metastatic and/or recurrent disease were evaluated. Serum levels of bFGF and VEGF were repeatedly measured using ELISA. The extent of target organ involvement and the kinetics of tumour volume growth were determined on consecutive computer tomography (CT) images.
RESULTS:: Patients with a tumour volume doubling time of less than 6 months showed a higher bFGF and VEGF serum level than others, independent of the number of sites involved and the extent of the metastatic disease.
CONCLUSIONS:: The data suggest a predictive value of serum bFGF and VEGF levels for the progression of disease in patients with untreated metastatic colorectal cancer. The results corroborate the importance of angiogenesis in the process of tumour growth. The serum levels might prove a useful tool in the quantitication of angiogenesis and might be of valuable information in the decision process of initiating palliative chemotherapy. It will be of considerable importance to investigate whether the serum bFGF and VEGF levels have a predictive value on the probability of response to cytotoxic therapy.
angiogenesis, colorectal carcinoma, tumour growth, serum bFGF, esrum VEGF
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  Y. Oh, R. S. Herbst, H. Burris, A. Cleverly, L. Musib, M. Lahn, and G. Bepler Enzastaurin, an Oral Serine/Threonine Kinase Inhibitor, As Second- or Third-Line Therapy of Non-Small-Cell Lung Cancer J. Clin. Oncol., March 1, 2008; 26(7): 1135 - 1141. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Sweeney, G. Liu, C. Yiannoutsos, J. Kolesar, D. Horvath, M. J. Staab, K. Fife, V. Armstrong, A. Treston, C. Sidor, et al. A Phase II Multicenter, Randomized, Double-Blind, Safety Trial Assessing the Pharmacokinetics, Pharmacodynamics, and Efficacy of Oral 2-Methoxyestradiol Capsules in Hormone-Refractory Prostate Cancer Clin. Cancer Res., September 15, 2005; 11(18): 6625 - 6633. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. L. Ince, A. M. Jubb, S. N. Holden, E. B. Holmgren, P. Tobin, M. Sridhar, H. I. Hurwitz, F. Kabbinavar, W. F. Novotny, K. J. Hillan, et al. Association of k-ras, b-raf, and p53 Status With the Treatment Effect of Bevacizumab J Natl Cancer Inst, July 6, 2005; 97(13): 981 - 989. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Grgic, I. Eichler, P. Heinau, H. Si, S. Brakemeier, J. Hoyer, and R. Kohler Selective Blockade of the Intermediate-Conductance Ca2+-Activated K+ Channel Suppresses Proliferation of Microvascular and Macrovascular Endothelial Cells and Angiogenesis In Vivo Arterioscler Thromb Vasc Biol, April 1, 2005; 25(4): 704 - 709. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Graziano and S. Cascinu Treatment of Metastatic Colorectal Cancer With Monoclonal Antibody to Vascular Endothelial Growth Factor: Does the Metastatic Site Make the Difference? J. Clin. Oncol., September 15, 2003; 21(18): 3542 - 3543. [Full Text] [PDF]
|
|
|
|
 |
|
 T. Ruotsalainen, H. Joensuu, K. Mattson, and P. Salven High Pretreatment Serum Concentration of Basic Fibroblast Growth Factor Is a Predictor of Poor Prognosis in Small Cell Lung Cancer Cancer Epidemiol. Biomarkers Prev., November 1, 2002; 11(11): 1492 - 1495. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Berglund, D. Molin, A. Larsson, R. Einarsson, and B. Glimelius Tumour markers as early predictors of response to chemotherapy in advanced colorectal carcinoma Ann. Onc., September 1, 2002; 13(9): 1430 - 1437. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. T.-P. Poon, S.-T. Fan, and J. Wong Clinical Implications of Circulating Angiogenic Factors in Cancer Patients J. Clin. Oncol., February 15, 2001; 19(4): 1207 - 1225. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Ugurel, G. Rappl, W. Tilgen, and U. Reinhold Increased Serum Concentration of Angiogenic Factors in Malignant Melanoma Patients Correlates With Tumor Progression and Survival J. Clin. Oncol., January 15, 2001; 19(2): 577 - 583. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Salven, A. Orpana, L. Teerenhovi, and H. Joensuu Simultaneous elevation in the serum concentrations of the angiogenic growth factors VEGF and bFGF is an independent predictor of poor prognosis in non-Hodgkin lymphoma: a single-institution study of 200 patients Blood, December 1, 2000; 96(12): 3712 - 3718. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. L. George, S. A. Eccles, M. G. Tutton, A. M. Abulafi, and R. I. Swift Correlation of Plasma and Serum Vascular Endothelial Growth Factor Levels with Platelet Count in Colorectal Cancer: Clinical Evidence of Platelet Scavenging? Clin. Cancer Res., August 1, 2000; 6(8): 3147 - 3152. [Abstract] [Full Text]
|
|
|
|
|
|
L. D. Ke, Y.-X. Shi, S.-A. Im, X. Chen, and W. K. A. Yung The Relevance of Cell Proliferation, Vascular Endothelial Growth Factor, and Basic Fibroblast Growth Factor Production to Angiogenesis and Tumorigenicity in Human Glioma Cell Lines Clin. Cancer Res., June 1, 2000; 6(6): 2562 - 2572. [Abstract] [Full Text]
|
|
|
|
|
|
Y. Kondo, S. Arii, A. Mori, M. Furutani, T. Chiba, and M. Imamura Enhancement of Angiogenesis, Tumor Growth, and Metastasis by Transfection of Vascular Endothelial Growth Factor into LoVo Human Colon Cancer Cell Line Clin. Cancer Res., February 1, 2000; 6(2): 622 - 630. [Abstract] [Full Text]
|
|
|
|
|
|
P. Salven, L. Teerenhovi, and H. Joensuu A High Pretreatment Serum Basic Fibroblast Growth Factor Concentration Is an Independent Predictor of Poor Prognosis in Non-Hodgkin's Lymphoma Blood, November 15, 1999; 94(10): 3334 - 3339. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Salven, A. Orpana, and H. Joensuu Leukocytes and Platelets of Patients with Cancer Contain High Levels of Vascular Endothelial Growth Factor Clin. Cancer Res., March 1, 1999; 5(3): 487 - 491. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Imoto, T. Osaki, S. Taga, A. Ohgami, Y. Ichiyoshi, and K. Yasumoto Vascular endothelial growth factor expression in non-small-cell lungcancer: Prognostic significance in squamous cell carcinoma J. Thorac. Cardiovasc. Surg., May 1, 1998; 115(5): 1007 - 1011. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Salven, L. Teerenhovi, and H. Joensuu A High Pretreatment Serum Vascular Endothelial Growth Factor Concentration Is Associated With Poor Outcome in Non-Hodgkin's Lymphoma Blood, October 15, 1997; 90(8): 3167 - 3172. [Abstract] [Full Text] [PDF]
|
|